億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0%
Aug 16, 2023 19:07 HKT |  |
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Aug 16, 2023 19:06 HKT | |
|
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成
Jul 26, 2023 19:00 HKT | |
|
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成
Jul 26, 2023 18:59 HKT | |
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Jul 26, 2023 18:58 HKT | |
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 20:19 HKT |  |
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 19:30 HKT | |
|
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Jul 20, 2023 16:00 HKT |  |
|
中国三大ICL服务提供商之一艾迪康于香港联交所主板正式挂牌
Jun 30, 2023 14:27 HKT |  |
|
中國三大ICL服務提供者之一艾迪康於香港聯交所主板正式掛牌
Jun 30, 2023 14:26 HKT | |
|
ADICON Holdings Limited One of the Top Three ICL Service Providers in China is Successfully Listed on Main Board of SEHK
Jun 30, 2023 14:25 HKT | |
|
医疗板块布局正当时，关注新股ICL龙头艾迪康带来的投资机遇
Jun 21, 2023 07:07 HKT | |
|
醫療板塊佈局正當時，關注新股ICL龍頭艾迪康帶來的投資機遇
Jun 21, 2023 07:06 HKT | |
|
艾迪康宣布于港交所主板上市计划 每股作价12.32港元
Jun 19, 2023 11:39 HKT | |
|
艾迪康宣佈於港交所主板上市計劃 每股作價12.32港元
Jun 19, 2023 11:38 HKT | |
|
ADICON Announces Proposed Listing on the Main Board of The Stock Exchange of Hong Kong at an Offer Price of HK$12.32 Per Share
Jun 19, 2023 11:37 HKT | |
|
Asensus Shares First Quarter Results and Future Plans
Jun 01, 2023 21:40 HKT |  |
|
2023 ASCO和BIO上的Avance Clinical：早期肿瘤治疗试验越来越复杂，对患者的需求也越来越大
May 30, 2023 11:00 HKT |  |
|
2023 ASCO和BIO上的Avance Clinical：早期腫瘤治療試驗越來越複雜，對患者的需求也越來越大
May 30, 2023 11:00 HKT | |
|
ASCO & BIO 2023에서 아방스 임상: 점점 더 정교해지고 더 많은 환자를 요구하는 초기 단계 종양학 시험
May 30, 2023 11:00 HKT | |
|